Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | Director | June 24, 2026 | June 26, 2026 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 05, 2026 | June 09, 2026 |
| Carisma Therapeutics Inc.CARM · Entity 74418 | Director | June 26, 2024 | June 27, 2024 |
| Codiak BioSciences, Inc.CDAK · Entity 114958 | Director | February 17, 2021 | February 17, 2021 |
| NextCure, Inc.NXTC · Entity 7461 | Director | June 11, 2020 | June 15, 2020 |
| Oncorus, Inc.ONCR · Entity 112213 | Director | October 01, 2020 | October 01, 2020 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | June 17, 2024 | June 20, 2024 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | February 07, 2024 | February 09, 2024 |
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Director | June 12, 2025 | June 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,548 |
Reported balance
After 2026-06-24 transaction · row 1
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 15,527 · Balance 111,548 F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2036-06-23 | Direct | 22,714 |
Reported balance
After 2026-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-24 · Grant · Acquired 22,714 · Balance 22,714 F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.
F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.
CRISPR Therapeutics AG
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05 | Direct | 13,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Carisma Therapeutics Inc.
Report date June 26, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2034-06-26 | Direct | 19,350 |
Reported balance
After 2024-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-26 · Grant · Acquired 19,350 · Balance 19,350 F1: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director.
Codiak BioSciences, Inc.
Report date February 17, 2021 · Filed February 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,761 |
Reported balance
After 2021-02-17 transaction · row 1
1 source rowRow 1 · 2021-02-17 · Purchase · Acquired 4,761 · Balance 4,761 |
NextCure, Inc.
Report date June 11, 2020 · Filed June 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.13 · Expires 2030-06-10 | Direct | 14,250 |
Reported balance
After 2020-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-11 · Grant · Acquired 14,250 · Balance 14,250 F1: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders.
Oncorus, Inc.
Report date October 01, 2020 · Filed October 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2026-04-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2026-08-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Repare Therapeutics Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16 | Direct | 27,200 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 27,200 · Balance 27,200 F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.
Syndax Pharmaceuticals Inc
Report date February 07, 2024 · Filed February 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,836 |
Reported balance
After 2024-02-07 transaction · row 1
1 source rowRow 1 · 2024-02-07 · Grant · Acquired 17,000 · Balance 34,836 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.
Werewolf Therapeutics, Inc.
Report date June 12, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-06-11 | Direct | 27,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 27,000 · Balance 27,000 F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 20, 2022 Filed Sep 21, 2022 20:18 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 59,649 | $10.90 | $650,174.10 |
DisclosureSEC source: 0001562180-22-006788 · primarydocument.xml · nonDerivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:18 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 114,339 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001562180-22-006788 · primarydocument.xml · derivative · entry 5 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 114,339 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:18 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 114,339 | $23.03 | $2,633,044.23 |
DisclosureSEC source: 0001562180-22-006788 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 774,958 options to purchase shares of common stock that are vested and immediately exercisable and a total of 370,042 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $22.50 to $23.35 Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:18 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 114,339 | $10.90 | $1,246,295.10 |
DisclosureSEC source: 0001562180-22-006788 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 71,966 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · derivative · entry 12 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,966 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 53,034 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · derivative · entry 11 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,034 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 53,034 | $23.22 | $1,231,422.96 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · nonDerivative · entry 8 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 948,946 options to purchase shares of common stock that are vested and immediately exercisable and a total of 245,042 options to purchase shares of common stock that have not yet vested. F4 · price: The sale prices ranged from $22.96 to $23.99 Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 53,034 | $10.90 | $578,070.60 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · nonDerivative · entry 7 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 71,966 | $23.22 | $1,671,014.54 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · nonDerivative · entry 6 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 948,946 options to purchase shares of common stock that are vested and immediately exercisable and a total of 245,042 options to purchase shares of common stock that have not yet vested. F4 · price: The sale prices ranged from $22.96 to $23.99 Read SEC document |
| September 16, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 71,966 | $7.20 | $518,155.20 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · nonDerivative · entry 5 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 66,775 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · derivative · entry 10 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,775 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 66,775 | $24.20 | $1,616,035.13 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · nonDerivative · entry 4 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 948,946 options to purchase shares of common stock that are vested and immediately exercisable and a total of 245,042 options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $23.36 to $24.64 Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 66,775 | $7.20 | $480,780.00 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · nonDerivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 87,645 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · derivative · entry 9 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,645 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 87,645 | $23.80 | $2,085,854.59 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 948,946 options to purchase shares of common stock that are vested and immediately exercisable and a total of 245,042 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $23.36 to $24.01 Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 87,645 | $7.20 | $631,044.00 |
DisclosureSEC source: 0001562180-22-006706 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 62,292 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-22-005475 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,292 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 62,292 | $19.00 | $1,183,429.65 |
DisclosureSEC source: 0001562180-22-005475 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,200,616 options to purchase shares of common stock that are vested and immediately exercisable and a total of 397,792 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $18.61 to $19.38 Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 62,292 | $7.20 | $448,502.40 |
DisclosureSEC source: 0001562180-22-005475 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 00:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 10,192 | $0.00 Strike: $36.79 | $0.00 |
DisclosureSEC source: 0001209191-22-038553 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,192 Underlying: Common Stock · 10,192 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option award was granted on June 16, 2022. The shares underlying the award shall vest in full on the earlier of June 16, 2023 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:41 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 11,600 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000899243-22-020987 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,600 Underlying: Common Stock · 11,600 shares Expires 2032-05-31 F1 · derivative.exercise_date: The option was granted on June 1, 2022. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| May 13, 2022 Filed May 16, 2022 23:25 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 49,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001209191-22-029362 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Shares · 49,000 shares Expires 2032-05-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 16,188 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024674 · doc4.xml · derivative · entry 5 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494 Underlying: Common Stock · 16,188 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. F5 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/12 of the shares underlying the award vested as of June 28, 2018, with the remainder of the shares vesting in equal quarterly installments following June 28, 2018 through March 28, 2021. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 10,754 | $67.03 | $720,887.94 |
DisclosureSEC source: 0001209191-22-024674 · doc4.xml · nonDerivative · entry 4 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,976 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.58 to $67.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 7,104 | $66.07 | $469,355.60 |
DisclosureSEC source: 0001209191-22-024674 · doc4.xml · nonDerivative · entry 3 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,730 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.56 to $66.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 3,102 | $65.24 | $202,372.31 |
DisclosureSEC source: 0001209191-22-024674 · doc4.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,834 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.55 to $65.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 16,188 | $16.00 | $259,008.00 |
DisclosureSEC source: 0001209191-22-024674 · doc4.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 3,128 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · derivative · entry 8 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,128 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 3,128 | $18.29 | $57,219.88 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 6 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested. F5 · price: The sale prices ranged from $17.75 to $19.17. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 3,128 | $10.90 | $34,095.20 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 5 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2022 Filed Apr 13, 2022 20:09 UTC Amendment | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 3,128 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-22-003383 · primarydocument.xml · derivative · entry 4 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,128 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. F2 · derivative.exercise_date: This option is fully vested. F1 · derivative.expiration_date: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. Read SEC document |
| April 04, 2022 Filed Apr 13, 2022 20:09 UTC Amendment | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 3,128 | $7.20 | $22,521.60 |
DisclosureSEC source: 0001562180-22-003383 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 70,545 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · derivative · entry 7 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,545 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 70,545 | $17.46 | $1,231,567.56 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 4 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested. F4 · price: The sale prices ranged from $17.18 to $17.69. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 70,545 | $10.90 | $768,940.50 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 24,500 | $17.44 | $427,314.30 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $17.19 to $17.66. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 6,000 | $17.44 | $104,633.40 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $17.21 to $17.62. Read SEC document |
| April 01, 2022 Filed Apr 13, 2022 20:09 UTC Amendment | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 70,545 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-22-003383 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,545 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. F2 · derivative.exercise_date: This option is fully vested. F1 · derivative.expiration_date: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. Read SEC document |
| April 01, 2022 Filed Apr 13, 2022 20:09 UTC Amendment | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 70,545 | $7.20 | $507,924.00 |
DisclosureSEC source: 0001562180-22-003383 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 160,000 | $15.79 Strike: $15.79 | $2,526,400.00 |
DisclosureSEC source: 0001562180-22-001080 · primarydocument.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The securities awarded on 02/02/2022 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 100,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/02/2022. Options to purchase 60,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 16,188 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-22-002557 · doc4.xml · derivative · entry 6 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,682 Underlying: Common Stock · 16,188 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. F6 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/12 of the shares underlying the award vested as of June 28, 2018, with the remainder of the shares vesting in equal quarterly installments following June 28, 207 through March 28, 2021. Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 2,108 | $67.69 | $142,696.21 |
DisclosureSEC source: 0000899243-22-002557 · doc4.xml · nonDerivative · entry 5 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,748 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.5400 to $67.9600, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, the number of shares sold at each separate price within the range set forth in this footnote (5). Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 5,100 | $67.28 | $343,143.81 |
DisclosureSEC source: 0000899243-22-002557 · doc4.xml · nonDerivative · entry 4 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,856 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.5300 to $67.5200, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, the number of shares sold at each separate price within the range set forth in this footnote (4). Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 3,833 | $65.24 | $250,071.44 |
DisclosureSEC source: 0000899243-22-002557 · doc4.xml · nonDerivative · entry 3 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,956 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.9200 to $65.8900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, the number of shares sold at each separate price within the range set forth in this footnote (3). Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 9,919 | $64.33 | $638,109.11 |
DisclosureSEC source: 0000899243-22-002557 · doc4.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,789 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.9000 to $64.8800, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 16,188 | $16.00 | $259,008.00 |
DisclosureSEC source: 0000899243-22-002557 · doc4.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 35,156 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001562180-21-007810 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,156 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 35,156 | $20.00 | $703,120.00 |
DisclosureSEC source: 0001562180-21-007810 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,305,602 options to purchase shares of common stock that are vested and immediately exercisable and a total of 339,083 options to purchase shares of common stock that have not yet vested. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 35,156 | $10.90 | $383,200.40 |
DisclosureSEC source: 0001562180-21-007810 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 20:35 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 50 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-006038 · primarydocument.xml · derivative · entry 6 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.